AC Immune and Takeda sign $100M upfront, $2.1B potential deal for Alzheimer's immunotherapies.
AC Immune and Takeda have agreed on an exclusive, worldwide option and license deal for AC Immune's active immunotherapies targeting toxic amyloid-beta forms, including ACI-24.060, for Alzheimer's disease treatment. The deal involves a $100 million upfront payment to AC Immune and potential milestone payments of up to $2.1 billion. Takeda will be responsible for further clinical development, global regulatory activities, and worldwide commercialization.
May 13, 2024
9 Articles